
AstraZeneca's Airsupra cuts risk of severe exacerbations by 47% in patients with milder asthma
In October, AstraZeneca revealed that early results from a phase 3 trial of its dual-drug asthma inhaler Airsupra were so convincing that an independent committee decided to halt the study based on evidence of “overwhelming efficacy.” On Monday, AZ filled …